Geode Capital Management, LLC Adial Pharmaceuticals, Inc. Transaction History

Geode Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.03 - $46.0 $47 - $72,450	1,575 Added 1.16%	137,464 $48,000
Q2 2022 Aug 12, 2022	BUY	$28.0 - $53.25 $22,036 - $41,907	787 Added 0.58%	135,889 $182,000
Q1 2022 May 13, 2022	BUY	$45.0 - $69.0 $259,875 - $398,475	5,775 Added 4.47%	135,102 $271,000
Q4 2021 Feb 11, 2022	BUY	$62.25 - $104.5 $2.07 Million - $3.47 Million	33,250 Added 34.61%	129,327 $349,000
Q3 2021 Nov 12, 2021	BUY	$57.75 - $116.75 $452,240 - $914,269	7,831 Added 8.87%	96,077 $412,000
Q2 2021 Aug 13, 2021	BUY	$50.5 - $78.25 $518,180 - $802,923	10,261 Added 13.16%	88,246 $225,000
Q1 2019 May 14, 2019	BUY	N/A	64,404 Added 474.22%	77,985 $267,000
Q4 2018 Feb 13, 2019	BUY	N/A	13,581 New	13,581 $69,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $26M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.